Price T Rowe Associates Inc Capricor Therapeutics, Inc. Transaction History
Price T Rowe Associates Inc
- $935 Billion
- Q3 2025
A detailed history of Price T Rowe Associates Inc transactions in Capricor Therapeutics, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 20,574 shares of CAPR stock, worth $115,831. This represents 0.0% of its overall portfolio holdings.
Number of Shares
20,574
Previous 19,018
8.18%
Holding current value
$115,831
Previous $189,000
21.16%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding CAPR
# of Institutions
141Shares Held
13.3MCall Options Held
4MPut Options Held
2.76M-
Vanguard Group Inc Valley Forge, PA2.21MShares$12.4 Million0.0% of portfolio
-
Black Rock Inc. New York, NY1.63MShares$9.17 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA962KShares$5.41 Million0.0% of portfolio
-
State Street Corp Boston, MA801KShares$4.51 Million0.0% of portfolio
-
Morgan Stanley New York, NY552KShares$3.11 Million0.0% of portfolio
About CAPRICOR THERAPEUTICS, INC.
- Ticker CAPR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 24,346,200
- Market Cap $137M
- Description
- Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for th...